- Home
- CAN vs GLUE Comparison
CAN vs GLUE Comparison
Compare CAN & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- GLUE
- Stock Information
- Founded
- CAN 2013
- GLUE 2019
- Country
- CAN Singapore
- GLUE United States
- Employees
- CAN N/A
- GLUE N/A
- Industry
- CAN Semiconductors
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- CAN Technology
- GLUE Health Care
- Exchange
- CAN Nasdaq
- GLUE Nasdaq
- Market Cap
- CAN 425.9M
- GLUE 475.5M
- IPO Year
- CAN 2019
- GLUE 2021
- Fundamental
- Price
- CAN $2.14
- GLUE $9.86
- Analyst Decision
- CAN Strong Buy
- GLUE Buy
- Analyst Count
- CAN 4
- GLUE 3
- Target Price
- CAN $3.38
- GLUE $14.67
- AVG Volume (30 Days)
- CAN 20.8M
- GLUE 897.9K
- Earning Date
- CAN 11-20-2024
- GLUE 11-07-2024
- Dividend Yield
- CAN N/A
- GLUE N/A
- EPS Growth
- CAN N/A
- GLUE N/A
- EPS
- CAN N/A
- GLUE N/A
- Revenue
- CAN $229,630,000.00
- GLUE $14,975,000.00
- Revenue This Year
- CAN $23.60
- GLUE N/A
- Revenue Next Year
- CAN $60.15
- GLUE N/A
- P/E Ratio
- CAN N/A
- GLUE N/A
- Revenue Growth
- CAN N/A
- GLUE N/A
- 52 Week Low
- CAN $0.72
- GLUE $2.95
- 52 Week High
- CAN $3.50
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- CAN 66.06
- GLUE 63.66
- Support Level
- CAN $1.73
- GLUE $8.04
- Resistance Level
- CAN $2.26
- GLUE $10.70
- Average True Range (ATR)
- CAN 0.27
- GLUE 0.76
- MACD
- CAN 0.03
- GLUE 0.07
- Stochastic Oscillator
- CAN 85.54
- GLUE 74.59
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.